A large number of hepatocellular cancer cells and hepatitis infected cells exhibit increased expression of PD-1/PD-L1, which makes PD-1/PD-L1-targeted inhibitors as the promising treatment strategy. This evidence concerns the gene CD274 and hepatitis A virus infection.